ISPOR Releases Top 10 HEOR Trends Report for 2022-2023

By HEOR Staff Writer

January 17, 2023

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a renowned professional society in Health Economics and Outcomes Research (HEOR). Biennially, it publishes a report, outlining the ISPOR Top 10 HEOR Trends. This article explores the 2022-2023 top trends, heavily influenced by the COVID-19 pandemic, and their implications for the healthcare industry.

Real-world Evidence (RWE) – The Number One Trend

RWE has been identified as the top trend for 2022-2023. Its significance has grown due to its crucial role in addressing the pandemic. Health data, which is integral to RWE, also joins the trends list at number nine.

Health Equity – A New Entrant in the Top Trends

The pandemic has starkly highlighted health disparities and their devastating impact. As a result, health equity has emerged as a top trend, ranking third on the list.

Public Health and Health Technology Assessment (HTA) – Rising Trends

Public health has also been elevated in the trends list, ranking seventh, no doubt due to the pandemic’s impact. HTA enters the list at number eight, underlining the importance of evaluating healthcare interventions.

Artificial Intelligence – A Key Player in the Top Trends

Artificial Intelligence (AI) has made its mark, joining the top trends at number ten. It’s clear that healthcare data and AI are becoming increasingly intertwined, driving innovation and efficiency in the sector.


These top trends in HEOR provide valuable insights for all healthcare stakeholders, from researchers and academicians to life sciences industry professionals and patients. They highlight the importance of informed health decisions backed by rigorous, proven methodologies.

 

Reference url

Recent Posts

PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies

By João L. Carapinha

April 23, 2026

Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...